Does artificial intelligence have a place in precision oncology?
Applications in artificial intelligence have the potential to transform precision oncology, but data quality and clinical validation of tools are still challenging
The growing role of AI in breast cancer
The rapidly increasing integration of AI into many aspects of breast cancer management calls for urgent definition of expected levels of evidence and bespoke regulatory and reimbursement processes
Machine learning may help to uncover new immunotherapy targets
A study proposes a model that is able to learn broad aspects of cancer–immune interactions from early phase trial data
The value of real-world data to inform cancer research and care
Well-designed real-world observational studies are hypothesis-generating and impact therapeutic decisions
Digital health technologies help revolutionise patient-centred cancer care
Recent studies show how digital health apps enhance the patient experience, and improve multiple quality of life domains and in some cases, adherence to treatment, but their integration into the healthcare system is still a challenge
The patient view on digitalisation in oncology
Digital tools offer potential solutions to personalise the patient journey, but more effort is needed to integrate them into current healthcare settings
Performance data from AI tools show progress in oncology
Cancer imaging and identification of predictive biomarkers are the best performed tasks reported in studies presented at ESMO Congress 2023
The future of real-world research is now
ESMO is at the forefront of digital oncology, with some initiatives that support oncologists navigating the emerging opportunities in the field of real-world data research
Does AI hold the future of early cancer detection?
Technology promises to improve understanding of cancer risk and lesion biology, but clear regulation is urged to implement innovation in cancer screening programmes
Innovation is creating new ways to support oncologists
How ESMO is transforming the challenges from the COVID-19 pandemic into opportunities to re-shape the future of the oncology community